The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Kidney (Renal) Fibrosis-Global Market Insights and Sales Trends 2024
Synopsis
Kidney fibrosis is characterized by excessive production and deposition of extracellular matrix (ECM) proteins mainly in the kidney interstitium and results in structural damage, impairment of renal function, and eventually end-stage renal disease (ESRD).
The global Kidney (Renal) Fibrosis market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Kidney (Renal) Fibrosis in various end use industries. The expanding demands from the Research Center, Hospital and Clinic,, are propelling Kidney (Renal) Fibrosis market. Angiotensin Converting enzyme (ACE) Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Pirfenidone segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Kidney (Renal) Fibrosis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Kidney (Renal) Fibrosis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Kidney (Renal) Fibrosis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Kidney (Renal) Fibrosis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Kidney (Renal) Fibrosis covered in this report include Merck, Pfizer, Roche, InterMune, Galectin Therapeutics, La Jolla Pharmaceutical Company, ProMetic Life-Sciences Inc., BioLine Rx Ltd and Genzyme Corporation, etc.
The global Kidney (Renal) Fibrosis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
Pfizer
Roche
InterMune
Galectin Therapeutics
La Jolla Pharmaceutical Company
ProMetic Life-Sciences Inc.
BioLine Rx Ltd
Genzyme Corporation
Global Kidney (Renal) Fibrosis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Kidney (Renal) Fibrosis market, Segment by Type:
Angiotensin Converting enzyme (ACE) Inhibitors
Pirfenidone
Renin Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Vasopeptidase Inhibitors
Global Kidney (Renal) Fibrosis market, by Application
Research Center
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Kidney (Renal) Fibrosis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Kidney fibrosis is characterized by excessive production and deposition of extracellular matrix (ECM) proteins mainly in the kidney interstitium and results in structural damage, impairment of renal function, and eventually end-stage renal disease (ESRD).
The global Kidney (Renal) Fibrosis market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Kidney (Renal) Fibrosis in various end use industries. The expanding demands from the Research Center, Hospital and Clinic,, are propelling Kidney (Renal) Fibrosis market. Angiotensin Converting enzyme (ACE) Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Pirfenidone segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Kidney (Renal) Fibrosis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Kidney (Renal) Fibrosis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Kidney (Renal) Fibrosis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Kidney (Renal) Fibrosis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Kidney (Renal) Fibrosis covered in this report include Merck, Pfizer, Roche, InterMune, Galectin Therapeutics, La Jolla Pharmaceutical Company, ProMetic Life-Sciences Inc., BioLine Rx Ltd and Genzyme Corporation, etc.
The global Kidney (Renal) Fibrosis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
Pfizer
Roche
InterMune
Galectin Therapeutics
La Jolla Pharmaceutical Company
ProMetic Life-Sciences Inc.
BioLine Rx Ltd
Genzyme Corporation
Global Kidney (Renal) Fibrosis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Kidney (Renal) Fibrosis market, Segment by Type:
Angiotensin Converting enzyme (ACE) Inhibitors
Pirfenidone
Renin Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Vasopeptidase Inhibitors
Global Kidney (Renal) Fibrosis market, by Application
Research Center
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Kidney (Renal) Fibrosis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Kidney (Renal) Fibrosis
1.1 Kidney (Renal) Fibrosis Market Overview
1.1.1 Kidney (Renal) Fibrosis Product Scope
1.1.2 Kidney (Renal) Fibrosis Market Status and Outlook
1.2 Global Kidney (Renal) Fibrosis Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Kidney (Renal) Fibrosis Market Size by Region (2018-2029)
1.4 Global Kidney (Renal) Fibrosis Historic Market Size by Region (2018-2023)
1.5 Global Kidney (Renal) Fibrosis Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Kidney (Renal) Fibrosis Market Size (2018-2029)
1.6.1 North America Kidney (Renal) Fibrosis Market Size (2018-2029)
1.6.2 Europe Kidney (Renal) Fibrosis Market Size (2018-2029)
1.6.3 Asia-Pacific Kidney (Renal) Fibrosis Market Size (2018-2029)
1.6.4 Latin America Kidney (Renal) Fibrosis Market Size (2018-2029)
1.6.5 Middle East & Africa Kidney (Renal) Fibrosis Market Size (2018-2029)
2 Kidney (Renal) Fibrosis Market by Type
2.1 Introduction
2.1.1 Angiotensin Converting enzyme (ACE) Inhibitors
2.1.2 Pirfenidone
2.1.3 Renin Inhibitors
2.1.4 Angiotensin II Receptor Blockers (ARBs)
2.1.5 Vasopeptidase Inhibitors
2.2 Global Kidney (Renal) Fibrosis Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Kidney (Renal) Fibrosis Historic Market Size by Type (2018-2023)
2.2.2 Global Kidney (Renal) Fibrosis Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Kidney (Renal) Fibrosis Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Kidney (Renal) Fibrosis Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Kidney (Renal) Fibrosis Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Kidney (Renal) Fibrosis Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Kidney (Renal) Fibrosis Revenue Breakdown by Type (2018-2029)
3 Kidney (Renal) Fibrosis Market Overview by Application
3.1 Introduction
3.1.1 Research Center
3.1.2 Hospital
3.1.3 Clinic
3.2 Global Kidney (Renal) Fibrosis Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Kidney (Renal) Fibrosis Historic Market Size by Application (2018-2023)
3.2.2 Global Kidney (Renal) Fibrosis Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Kidney (Renal) Fibrosis Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Kidney (Renal) Fibrosis Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Kidney (Renal) Fibrosis Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Kidney (Renal) Fibrosis Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Kidney (Renal) Fibrosis Revenue Breakdown by Application (2018-2029)
4 Kidney (Renal) Fibrosis Competition Analysis by Players
4.1 Global Kidney (Renal) Fibrosis Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Kidney (Renal) Fibrosis as of 2022)
4.3 Date of Key Players Enter into Kidney (Renal) Fibrosis Market
4.4 Global Top Players Kidney (Renal) Fibrosis Headquarters and Area Served
4.5 Key Players Kidney (Renal) Fibrosis Product Solution and Service
4.6 Competitive Status
4.6.1 Kidney (Renal) Fibrosis Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Merck
5.1.1 Merck Profile
5.1.2 Merck Main Business
5.1.3 Merck Kidney (Renal) Fibrosis Products, Services and Solutions
5.1.4 Merck Kidney (Renal) Fibrosis Revenue (US$ Million) & (2018-2023)
5.1.5 Merck Recent Developments
5.2 Pfizer
5.2.1 Pfizer Profile
5.2.2 Pfizer Main Business
5.2.3 Pfizer Kidney (Renal) Fibrosis Products, Services and Solutions
5.2.4 Pfizer Kidney (Renal) Fibrosis Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Recent Developments
5.3 Roche
5.3.1 Roche Profile
5.3.2 Roche Main Business
5.3.3 Roche Kidney (Renal) Fibrosis Products, Services and Solutions
5.3.4 Roche Kidney (Renal) Fibrosis Revenue (US$ Million) & (2018-2023)
5.3.5 InterMune Recent Developments
5.4 InterMune
5.4.1 InterMune Profile
5.4.2 InterMune Main Business
5.4.3 InterMune Kidney (Renal) Fibrosis Products, Services and Solutions
5.4.4 InterMune Kidney (Renal) Fibrosis Revenue (US$ Million) & (2018-2023)
5.4.5 InterMune Recent Developments
5.5 Galectin Therapeutics
5.5.1 Galectin Therapeutics Profile
5.5.2 Galectin Therapeutics Main Business
5.5.3 Galectin Therapeutics Kidney (Renal) Fibrosis Products, Services and Solutions
5.5.4 Galectin Therapeutics Kidney (Renal) Fibrosis Revenue (US$ Million) & (2018-2023)
5.5.5 Galectin Therapeutics Recent Developments
5.6 La Jolla Pharmaceutical Company
5.6.1 La Jolla Pharmaceutical Company Profile
5.6.2 La Jolla Pharmaceutical Company Main Business
5.6.3 La Jolla Pharmaceutical Company Kidney (Renal) Fibrosis Products, Services and Solutions
5.6.4 La Jolla Pharmaceutical Company Kidney (Renal) Fibrosis Revenue (US$ Million) & (2018-2023)
5.6.5 La Jolla Pharmaceutical Company Recent Developments
5.7 ProMetic Life-Sciences Inc.
5.7.1 ProMetic Life-Sciences Inc. Profile
5.7.2 ProMetic Life-Sciences Inc. Main Business
5.7.3 ProMetic Life-Sciences Inc. Kidney (Renal) Fibrosis Products, Services and Solutions
5.7.4 ProMetic Life-Sciences Inc. Kidney (Renal) Fibrosis Revenue (US$ Million) & (2018-2023)
5.7.5 ProMetic Life-Sciences Inc. Recent Developments
5.8 BioLine Rx Ltd
5.8.1 BioLine Rx Ltd Profile
5.8.2 BioLine Rx Ltd Main Business
5.8.3 BioLine Rx Ltd Kidney (Renal) Fibrosis Products, Services and Solutions
5.8.4 BioLine Rx Ltd Kidney (Renal) Fibrosis Revenue (US$ Million) & (2018-2023)
5.8.5 BioLine Rx Ltd Recent Developments
5.9 Genzyme Corporation
5.9.1 Genzyme Corporation Profile
5.9.2 Genzyme Corporation Main Business
5.9.3 Genzyme Corporation Kidney (Renal) Fibrosis Products, Services and Solutions
5.9.4 Genzyme Corporation Kidney (Renal) Fibrosis Revenue (US$ Million) & (2018-2023)
5.9.5 Genzyme Corporation Recent Developments
6 North America
6.1 North America Kidney (Renal) Fibrosis Market Size by Country (2018-2029)
6.2 the United States
6.3 Canada
7 Europe
7.1 Europe Kidney (Renal) Fibrosis Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Kidney (Renal) Fibrosis Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Kidney (Renal) Fibrosis Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Kidney (Renal) Fibrosis Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Kidney (Renal) Fibrosis Market Dynamics
11.1 Kidney (Renal) Fibrosis Industry Trends
11.2 Kidney (Renal) Fibrosis Market Drivers
11.3 Kidney (Renal) Fibrosis Market Challenges
11.4 Kidney (Renal) Fibrosis Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
